SAN FRANCISCO / Feb 09, 2023 / Business Wire / Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results for the fiscal 2023 third quarter ended December 31, 2022.
“Our clinical workflow tools saw record use last quarter, including our telehealth platform which served 375,000 unique active clinicians,” said Jeff Tangney, co-founder and CEO at Doximity. “We’re proud to help more physicians be more mobile and more productive than ever before.”
Fiscal 2023 Third Quarter Financial Highlights
All comparisons, unless otherwise noted, are to the three months ended December 31, 2021.
Financial Outlook
Doximity is providing guidance for its fiscal fourth quarter ending March 31, 2023 as follows:
Doximity is adjusting its guidance for its fiscal year ending March 31, 2023 as follows:
Doximity is providing preliminary guidance for its fiscal year ending March 31, 2024 as follows:
Conference Call Information
Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company’s Investor Relations page shortly after the call.
About Doximity
Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The Company's network members include over 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients. For more information, visit www.doximity.com.
Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the timing and scope of anticipated stock repurchases; (ii) the impact of the COVID-19 pandemic (including the impact to our industry or on our customers’ industries, impact on general economic conditions, and government responses, restrictions, and actions related to the pandemic); (iii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iv) our ability to attract new customers or retain existing customers; (v) the impact of our prioritization of our members’ interests; (vi) breaches in our security measures or unauthorized access to members’ data; (vii) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled “Risk Factors” in the Annual Report on Form 10-K that was filed with the SEC on May 27, 2022. Additional information will be provided in our Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2022. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
DOXIMITY, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) | |||||||
| December 31, 2022 |
| March 31, 2022 | ||||
Assets |
|
|
| ||||
Current assets: |
|
|
| ||||
Cash and cash equivalents | $ | 136,454 |
|
| $ | 112,809 |
|
Marketable securities |
| 664,511 |
|
|
| 685,304 |
|
Accounts receivable, net |
| 74,862 |
|
|
| 81,073 |
|
Prepaid expenses and other current assets |
| 17,120 |
|
|
| 19,439 |
|
Deferred contract costs, current |
| 5,572 |
|
|
| 5,512 |
|
Total current assets |
| 898,519 |
|
|
| 904,137 |
|
Property and equipment, net |
| 11,519 |
|
|
| 8,488 |
|
Deferred income tax assets |
| 40,338 |
|
|
| 48,558 |
|
Operating lease right-of-use assets |
| 14,357 |
|
|
| 1,087 |
|
Intangible assets, net |
| 33,034 |
|
|
| 7,909 |
|
Goodwill |
| 67,940 |
|
|
| 18,915 |
|
Other assets |
| 1,380 |
|
|
| 2,263 |
|
Total assets | $ | 1,067,087 |
|
| $ | 991,357 |
|
Liabilities and Stockholders’ Equity |
|
|
| ||||
Current liabilities: |
|
|
| ||||
Accounts payable | $ | 1,604 |
|
| $ | 463 |
|
Accrued expenses and other current liabilities |
| 33,151 |
|
|
| 25,270 |
|
Deferred revenue, current |
| 69,671 |
|
|
| 84,907 |
|
Operating lease liabilities, current |
| 1,458 |
|
|
| 642 |
|
Total current liabilities |
| 105,884 |
|
|
| 111,282 |
|
Deferred revenue, non-current |
| 140 |
|
|
| 78 |
|
Operating lease liabilities, non-current |
| 14,181 |
|
|
| 447 |
|
Contingent earn-out consideration liability, non-current |
| 15,625 |
|
|
| — |
|
Other liabilities, non-current |
| 1,083 |
|
|
| 956 |
|
Total liabilities |
| 136,913 |
|
|
| 112,763 |
|
Stockholders' Equity |
|
|
| ||||
Preferred stock |
| — |
|
|
| — |
|
Common stock |
| 193 |
|
|
| 192 |
|
Additional paid-in capital |
| 745,506 |
|
|
| 702,589 |
|
Accumulated other comprehensive loss |
| (18,742 | ) |
|
| (15,294 | ) |
Retained earnings |
| 203,217 |
|
|
| 191,107 |
|
Total stockholders' equity |
| 930,174 |
|
|
| 878,594 |
|
Total liabilities and stockholders’ equity | $ | 1,067,087 |
|
| $ | 991,357 |
|
DOXIMITY, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (unaudited) | |||||||||||||
| Three Months Ended December 31, |
| Nine Months Ended December 31, | ||||||||||
|
| 2022 |
|
| 2021 |
|
|
| 2022 |
|
| 2021 |
|
Revenue | $ | 115,262 |
| $ | 97,876 |
|
| $ | 308,086 |
| $ | 249,895 |
|
Cost of revenue(1) |
| 13,526 |
|
| 11,085 |
|
|
| 39,813 |
|
| 28,022 |
|
Gross profit |
| 101,736 |
|
| 86,791 |
|
|
| 268,273 |
|
| 221,873 |
|
Operating expenses(1): |
|
|
|
|
|
|
| ||||||
Research and development |
| 20,519 |
|
| 16,225 |
|
|
| 58,645 |
|
| 44,926 |
|
Sales and marketing |
| 33,220 |
|
| 25,698 |
|
|
| 90,375 |
|
| 66,230 |
|
General and administrative |
| 9,513 |
|
| 9,079 |
|
|
| 26,986 |
|
| 25,102 |
|
Total operating expenses |
| 63,252 |
|
| 51,002 |
|
|
| 176,006 |
|
| 136,258 |
|
Income from operations |
| 38,484 |
|
| 35,789 |
|
|
| 92,267 |
|
| 85,615 |
|
Other income, net |
| 2,461 |
|
| 20 |
|
|
| 4,173 |
|
| 485 |
|
Income before income taxes |
| 40,945 |
|
| 35,809 |
|
|
| 96,440 |
|
| 86,100 |
|
Provision for (benefit from) income taxes |
| 7,477 |
|
| (19,838 | ) |
|
| 14,290 |
|
| (31,957 | ) |
Net income | $ | 33,468 |
| $ | 55,647 |
|
| $ | 82,150 |
| $ | 118,057 |
|
Undistributed earnings attributable to participating securities |
| — |
|
| — |
|
|
| — |
|
| (21,866 | ) |
Net income attributable to Class A and Class B common stockholders, basic and diluted | $ | 33,468 |
| $ | 55,647 |
|
| $ | 82,150 |
| $ | 96,191 |
|
Net income per share attributable to Class A and Class B common stockholders: |
|
|
|
|
|
|
| ||||||
Basic | $ | 0.17 |
| $ | 0.30 |
|
| $ | 0.43 |
| $ | 0.62 |
|
Diluted | $ | 0.16 |
| $ | 0.26 |
|
| $ | 0.38 |
| $ | 0.53 |
|
Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders: |
|
|
|
|
|
|
| ||||||
Basic |
| 192,805 |
|
| 188,372 |
|
|
| 192,963 |
|
| 154,289 |
|
Diluted |
| 212,065 |
|
| 216,396 |
|
|
| 213,656 |
|
| 182,905 |
|
(1) Costs and expenses include stock-based compensation expense as follows (in thousands):
| Three Months Ended December 31, |
|
| Nine Months Ended December 31, | |||||||||
|
| 2022 |
|
| 2021 |
|
|
| 2022 |
|
| 2021 | |
Cost of revenue | $ | 2,695 |
| $ | 1,912 |
| $ | 7,209 |
| $ | 2,973 | ||
Research and development |
| 4,002 |
|
| 2,035 |
|
| 9,416 |
|
| 4,864 | ||
Sales and marketing |
| 4,856 |
|
| 2,681 |
|
| 11,912 |
|
| 5,575 | ||
General and administrative |
| 2,431 |
|
| 3,206 |
|
| 6,306 |
|
| 8,221 | ||
Total stock-based compensation expense | $ | 13,984 |
| $ | 9,834 |
| $ | 34,843 |
| $ | 21,633 |
DOXIMITY, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited) | |||||||||||||||
| Three Months Ended December 31, |
| Nine Months Ended December 31, | ||||||||||||
|
| 2022 |
|
|
| 2021 |
|
|
| 2022 |
|
|
| 2021 |
|
Cash flows from operating activities |
|
|
|
|
|
|
| ||||||||
Net income | $ | 33,468 |
|
| $ | 55,647 |
|
| $ | 82,150 |
|
| $ | 118,057 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
|
|
| ||||||||
Depreciation and amortization |
| 2,616 |
|
|
| 1,361 |
|
|
| 7,575 |
|
|
| 3,672 |
|
Deferred income taxes |
| 9,287 |
|
|
| (31,972 | ) |
|
| 9,392 |
|
|
| (31,972 | ) |
Stock-based compensation, net of amounts capitalized |
| 13,984 |
|
|
| 9,834 |
|
|
| 34,843 |
|
|
| 21,633 |
|
Non-cash lease expense |
| 538 |
|
|
| 288 |
|
|
| 1,490 |
|
|
| 857 |
|
Amortization of premium on marketable securities, net |
| 471 |
|
|
| 1,302 |
|
|
| 3,144 |
|
|
| 2,863 |
|
Loss on sale of marketable securities |
| 593 |
|
|
| 595 |
|
|
| 1,093 |
|
|
| 525 |
|
Amortization of deferred contract costs |
| 1,518 |
|
|
| 1,710 |
|
|
| 6,357 |
|
|
| 7,366 |
|
Other |
| 790 |
|
|
| (73 | ) |
|
| 797 |
|
|
| 120 |
|
Changes in operating assets and liabilities, net of effect of acquisition: |
|
|
|
|
|
|
| ||||||||
Accounts receivable |
| 3,997 |
|
|
| (14,021 | ) |
|
| 6,191 |
|
|
| (19,579 | ) |
Prepaid expenses and other assets |
| (1,727 | ) |
|
| 10,722 |
|
|
| 1,924 |
|
|
| (7,003 | ) |
Deferred contract costs |
| (4,067 | ) |
|
| (3,697 | ) |
|
| (6,409 | ) |
|
| (6,672 | ) |
Accounts payable, accrued expenses and other liabilities |
| 7,197 |
|
|
| 8,872 |
|
|
| 2,723 |
|
|
| 8,093 |
|
Deferred revenue |
| (19,970 | ) |
|
| (13,111 | ) |
|
| (18,098 | ) |
|
| (17,538 | ) |
Operating lease liabilities |
| 2 |
|
|
| (173 | ) |
|
| (209 | ) |
|
| (811 | ) |
Net cash provided by operating activities |
| 48,697 |
|
|
| 27,284 |
|
|
| 132,963 |
|
|
| 79,611 |
|
Cash flows from investing activities |
|
|
|
|
|
|
| ||||||||
Cash paid for acquisition |
| — |
|
|
| — |
|
|
| (53,500 | ) |
|
| — |
|
Purchases of property and equipment |
| (204 | ) |
|
| (611 | ) |
|
| (1,680 | ) |
|
| (852 | ) |
Internal-use software development costs |
| (1,012 | ) |
|
| (1,065 | ) |
|
| (3,478 | ) |
|
| (2,736 | ) |
Purchases of marketable securities |
| (39,080 | ) |
|
| (115,772 | ) |
|
| (130,257 | ) |
|
| (1,271,915 | ) |
Maturities of marketable securities |
| 10,576 |
|
|
| 6,066 |
|
|
| 35,014 |
|
|
| 41,617 |
|
Sales of marketable securities |
| 43,024 |
|
|
| 85,862 |
|
|
| 107,182 |
|
|
| 616,938 |
|
Net cash provided by (used in) investing activities |
| 13,304 |
|
|
| (25,520 | ) |
|
| (46,719 | ) |
|
| (616,948 | ) |
Cash flows from financing activities |
|
|
|
|
|
|
| ||||||||
Proceeds from issuance of common stock upon initial public offering after deducting underwriting discounts and commissions |
| — |
|
|
| — |
|
|
| — |
|
|
| 553,905 |
|
Proceeds from issuance of common stock upon exercise of stock options and common stock warrants |
| 1,871 |
|
|
| 4,174 |
|
|
| 7,455 |
|
|
| 9,234 |
|
Proceeds from issuance of common stock in connection with the employee stock purchase plan |
| — |
|
|
| — |
|
|
| 2,341 |
|
|
| — |
|
Taxes paid related to net share settlement of equity awards |
| (1,092 | ) |
|
| (380 | ) |
|
| (2,353 | ) |
|
| (436 | ) |
Repurchase of common stock |
| — |
|
|
| — |
|
|
| (70,042 | ) |
|
| (2,698 | ) |
Payments of deferred offering costs |
| — |
|
|
| — |
|
|
| — |
|
|
| (3,982 | ) |
Net cash provided by (used in) financing activities |
| 779 |
|
|
| 3,794 |
|
|
| (62,599 | ) |
|
| 556,023 |
|
Net increase in cash and cash equivalents |
| 62,780 |
|
|
| 5,558 |
|
|
| 23,645 |
|
|
| 18,686 |
|
Cash and cash equivalents, beginning of period |
| 73,674 |
|
|
| 79,521 |
|
|
| 112,809 |
|
|
| 66,393 |
|
Cash and cash equivalents, end of period | $ | 136,454 |
|
| $ | 85,079 |
|
| $ | 136,454 |
|
| $ | 85,079 |
|
Non-GAAP Financial Measures
To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP measures of financial performance:
We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.
Key Business Metrics1
1 The metric excludes the impact of the AMiON acquisition, which closed on April 1, 2022, including customers of, and subscription revenue generated from, the AMiON on-call scheduling and messaging application and was immaterial to the periods presented.
Reconciliation of GAAP to Non-GAAP Financial Measures
The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:
| Three Months Ended December 31, |
| Nine Months Ended December 31, | ||||||||||||
|
| 2022 |
|
|
| 2021 |
|
|
| 2022 |
|
|
| 2021 |
|
| (unaudited) | ||||||||||||||
| (in thousands, except percentages) | ||||||||||||||
Net income | $ | 33,468 |
|
| $ | 55,647 |
|
| $ | 82,150 |
|
| $ | 118,057 |
|
Adjusted to exclude the following: |
|
|
|
|
|
|
| ||||||||
Acquisition and other related expenses |
| — |
|
|
| — |
|
|
| 30 |
|
|
| — |
|
Stock-based compensation |
| 13,984 |
|
|
| 9,834 |
|
|
| 34,843 |
|
|
| 21,633 |
|
Depreciation and amortization |
| 2,616 |
|
|
| 1,361 |
|
|
| 7,575 |
|
|
| 3,672 |
|
Provision for (benefit from) income taxes |
| 7,477 |
|
|
| (19,838 | ) |
|
| 14,290 |
|
|
| (31,957 | ) |
Change in fair value of contingent earn-out consideration liability |
| 417 |
|
|
| — |
|
|
| 323 |
|
|
| — |
|
Other income, net |
| (2,461 | ) |
|
| (20 | ) |
|
| (4,173 | ) |
|
| (485 | ) |
Adjusted EBITDA | $ | 55,501 |
|
| $ | 46,984 |
|
| $ | 135,038 |
|
| $ | 110,920 |
|
|
|
|
|
|
|
|
| ||||||||
Revenue | $ | 115,262 |
|
| $ | 97,876 |
|
| $ | 308,086 |
|
| $ | 249,895 |
|
Net income margin |
| 29.0 | % |
|
| 56.9 | % |
|
| 26.7 | % |
|
| 47.2 | % |
Adjusted EBITDA margin |
| 48.2 | % |
|
| 48.0 | % |
|
| 43.8 | % |
|
| 44.4 | % |
| Three Months Ended December 31, |
| Nine Months Ended December 31, | ||||||||||||
|
| 2022 |
|
|
| 2021 |
|
|
| 2022 |
|
|
| 2021 |
|
| (unaudited) | ||||||||||||||
| (in thousands) | ||||||||||||||
Net cash provided by operating activities | $ | 48,697 |
|
| $ | 27,284 |
|
| $ | 132,963 |
|
| $ | 79,611 |
|
Purchases of property and equipment |
| (204 | ) |
|
| (611 | ) |
|
| (1,680 | ) |
|
| (852 | ) |
Internal-use software development costs |
| (1,012 | ) |
|
| (1,065 | ) |
|
| (3,478 | ) |
|
| (2,736 | ) |
Free cash flow | $ | 47,481 |
|
| $ | 25,608 |
|
| $ | 127,805 |
|
| $ | 76,023 |
|
Other cash flow components: |
|
|
|
|
|
|
| ||||||||
Net cash provided by (used in) investing activities | $ | 13,304 |
|
| $ | (25,520 | ) |
| $ | (46,719 | ) |
| $ | (616,948 | ) |
Net cash provided by (used in) financing activities | $ | 779 |
|
| $ | 3,794 |
|
| $ | (62,599 | ) |
| $ | 556,023 |
|
| Three Months Ended December 31, |
| Nine Months Ended December 31, | ||||||||||||
|
| 2022 |
|
|
| 2021 |
|
|
| 2022 |
|
|
| 2021 |
|
| (unaudited) | ||||||||||||||
| (in thousands, except per share data and percentages) | ||||||||||||||
GAAP cost of revenue | $ | 13,526 |
|
| $ | 11,085 |
|
| $ | 39,813 |
|
| $ | 28,022 |
|
Adjusted to exclude the following: |
|
|
|
|
|
|
| ||||||||
Stock-based compensation |
| (2,695 | ) |
|
| (1,912 | ) |
|
| (7,209 | ) |
|
| (2,973 | ) |
Amortization of acquired intangibles |
| (137 | ) |
|
| — |
|
|
| (410 | ) |
|
| — |
|
Non-GAAP cost of revenue | $ | 10,694 |
|
| $ | 9,173 |
|
| $ | 32,194 |
|
| $ | 25,049 |
|
|
|
|
|
|
|
|
| ||||||||
GAAP gross profit | $ | 101,736 |
|
| $ | 86,791 |
|
| $ | 268,273 |
|
| $ | 221,873 |
|
Adjusted to exclude the following: |
|
|
|
|
|
|
| ||||||||
Stock-based compensation |
| 2,695 |
|
|
| 1,912 |
|
|
| 7,209 |
|
|
| 2,973 |
|
Amortization of acquired intangibles |
| 137 |
|
|
| — |
|
|
| 410 |
|
|
| — |
|
Non-GAAP gross profit | $ | 104,568 |
|
| $ | 88,703 |
|
| $ | 275,892 |
|
| $ | 224,846 |
|
|
|
|
|
|
|
|
| ||||||||
GAAP gross margin |
| 88.3 | % |
|
| 88.7 | % |
|
| 87.1 | % |
|
| 88.8 | % |
Non-GAAP gross margin |
| 90.7 | % |
|
| 90.6 | % |
|
| 89.6 | % |
|
| 90.0 | % |
|
|
|
|
|
|
|
| ||||||||
GAAP research and development expense | $ | 20,519 |
|
| $ | 16,225 |
|
| $ | 58,645 |
|
| $ | 44,926 |
|
Adjusted to exclude the following: |
|
|
|
|
|
|
| ||||||||
Stock-based compensation |
| (4,002 | ) |
|
| (2,035 | ) |
|
| (9,416 | ) |
|
| (4,864 | ) |
Non-GAAP research and development expense | $ | 16,517 |
|
| $ | 14,190 |
|
| $ | 49,229 |
|
| $ | 40,062 |
|
|
|
|
|
|
|
|
| ||||||||
GAAP sales and marketing expense | $ | 33,220 |
|
| $ | 25,698 |
|
| $ | 90,375 |
|
| $ | 66,230 |
|
Adjusted to exclude the following: |
|
|
|
|
|
|
| ||||||||
Stock-based compensation |
| (4,856 | ) |
|
| (2,681 | ) |
|
| (11,912 | ) |
|
| (5,575 | ) |
Amortization of acquired intangibles |
| (1,061 | ) |
|
| (265 | ) |
|
| (3,185 | ) |
|
| (795 | ) |
Change in fair value of contingent earn-out consideration liability |
| (417 | ) |
|
| — |
|
|
| (323 | ) |
|
| — |
|
Non-GAAP sales and marketing expense | $ | 26,886 |
|
| $ | 22,752 |
|
| $ | 74,955 |
|
| $ | 59,860 |
|
|
|
|
|
|
|
|
| ||||||||
GAAP general and administrative expense | $ | 9,513 |
|
| $ | 9,079 |
|
| $ | 26,986 |
|
| $ | 25,102 |
|
Adjusted to exclude the following: |
|
|
|
|
|
|
| ||||||||
Acquisition and other related expenses |
| — |
|
|
| — |
|
|
| (30 | ) |
|
| — |
|
Stock-based compensation |
| (2,431 | ) |
|
| (3,206 | ) |
|
| (6,306 | ) |
|
| (8,221 | ) |
Non-GAAP general and administrative expense | $ | 7,082 |
|
| $ | 5,873 |
|
| $ | 20,650 |
|
| $ | 16,881 |
|
|
|
|
|
|
|
|
| ||||||||
GAAP operating expense | $ | 63,252 |
|
| $ | 51,002 |
|
| $ | 176,006 |
|
| $ | 136,258 |
|
Adjusted to exclude the following: |
|
|
|
|
|
|
| ||||||||
Acquisition and other related expenses |
| — |
|
|
| — |
|
|
| (30 | ) |
|
| — |
|
Stock-based compensation |
| (11,289 | ) |
|
| (7,922 | ) |
|
| (27,634 | ) |
|
| (18,660 | ) |
Amortization of acquired intangibles |
| (1,061 | ) |
|
| (265 | ) |
|
| (3,185 | ) |
|
| (795 | ) |
Change in fair value of contingent earn-out consideration liability |
| (417 | ) |
|
| — |
|
|
| (323 | ) |
|
| — |
|
Non-GAAP operating expense | $ | 50,485 |
|
| $ | 42,815 |
|
| $ | 144,834 |
|
| $ | 116,803 |
|
|
|
|
|
|
|
|
| ||||||||
GAAP operating income | $ | 38,484 |
|
| $ | 35,789 |
|
| $ | 92,267 |
|
| $ | 85,615 |
|
Adjusted to exclude the following: |
|
|
|
|
|
|
| ||||||||
Acquisition and other related expenses |
| — |
|
|
| — |
|
|
| 30 |
|
|
| — |
|
Stock-based compensation |
| 13,984 |
|
|
| 9,834 |
|
|
| 34,843 |
|
|
| 21,633 |
|
Amortization of acquired intangibles |
| 1,198 |
|
|
| 265 |
|
|
| 3,595 |
|
|
| 795 |
|
Change in fair value of contingent earn-out consideration liability |
| 417 |
|
|
| — |
|
|
| 323 |
|
|
| — |
|
Non-GAAP operating income | $ | 54,083 |
|
| $ | 45,888 |
|
| $ | 131,058 |
|
| $ | 108,043 |
|
|
|
|
|
|
|
|
| ||||||||
GAAP net income | $ | 33,468 |
|
| $ | 55,647 |
|
| $ | 82,150 |
|
| $ | 118,057 |
|
Adjusted to exclude the following: |
|
|
|
|
|
|
| ||||||||
Acquisition and other related expenses |
| — |
|
|
| — |
|
|
| 30 |
|
|
| — |
|
Stock-based compensation |
| 13,984 |
|
|
| 9,834 |
|
|
| 34,843 |
|
|
| 21,633 |
|
Amortization of acquired intangibles |
| 1,198 |
|
|
| 265 |
|
|
| 3,595 |
|
|
| 795 |
|
Change in fair value of contingent earn-out consideration liability |
| 417 |
|
|
| — |
|
|
| 323 |
|
|
| — |
|
Income tax effect of non-GAAP adjustments (1) |
| (3,276 | ) |
|
| (2,121 | ) |
|
| (8,146 | ) |
|
| (4,710 | ) |
Non-GAAP net income | $ | 45,791 |
|
| $ | 63,625 |
|
| $ | 112,795 |
|
| $ | 135,775 |
|
Non-GAAP net income margin |
| 39.7 | % |
|
| 65.0 | % |
|
| 36.6 | % |
|
| 54.3 | % |
|
|
|
|
|
|
|
| ||||||||
GAAP undistributed earnings attributable to participating securities | $ | — |
|
| $ | — |
|
| $ | — |
|
| $ | (21,866 | ) |
Impact on undistributed earnings attributable to participating securities due to non-GAAP adjustments |
| — |
|
|
| — |
|
|
| — |
|
|
| (2,436 | ) |
Non-GAAP undistributed earnings attributable to participating securities | $ | — |
|
| $ | — |
|
| $ | — |
|
| $ | (24,302 | ) |
|
|
|
|
|
|
|
| ||||||||
Non-GAAP net income | $ | 45,791 |
|
| $ | 63,625 |
|
| $ | 112,795 |
|
| $ | 135,775 |
|
Non-GAAP undistributed earnings attributable to participating securities |
| — |
|
|
| — |
|
|
| — |
|
|
| (24,302 | ) |
Non-GAAP net income attributable to Class A and Class B stockholders, basic and diluted | $ | 45,791 |
|
| $ | 63,625 |
|
| $ | 112,795 |
|
| $ | 111,473 |
|
|
|
|
|
|
|
|
| ||||||||
Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders: |
|
|
|
|
|
|
| ||||||||
Basic |
| 192,805 |
|
|
| 188,372 |
|
|
| 192,963 |
|
|
| 154,289 |
|
Diluted |
| 212,065 |
|
|
| 216,396 |
|
|
| 213,656 |
|
|
| 182,905 |
|
|
|
|
|
|
|
|
| ||||||||
Non-GAAP net income per share attributable to Class A and Class B stockholders: |
|
|
|
|
|
|
| ||||||||
Basic | $ | 0.24 |
|
| $ | 0.34 |
|
| $ | 0.58 |
|
| $ | 0.72 |
|
Diluted | $ | 0.22 |
|
| $ | 0.29 |
|
| $ | 0.53 |
|
| $ | 0.61 |
|
(1) For the three and nine months ended December 31, 2022 and 2021, management used an estimated annual effective non-GAAP tax rate of 21.0%.
Last Trade: | US$49.92 |
Daily Change: | 0.02 0.04 |
Daily Volume: | 139,751 |
Market Cap: | US$6.400B |
November 07, 2024 October 31, 2024 August 08, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB